$1.70
+0.03 (+1.80%)
Open$1.67
Previous Close$1.67
Day High$1.72
Day Low$1.67
52W High$10.83
52W Low$0.89
Volume—
Avg Volume111.8K
Market Cap29.72M
P/E Ratio—
EPS$-2.68
SectorBiotechnology
Analyst Ratings
Strong Buy
5 analysts
Price Target
+2,571.8% upside
Current
$1.70
$1.70
Target
$45.42
$45.42
$30.66
$45.42 avg
$56.99
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 18.47M | 17.78M | 17.86M |
| Net Income | 823.9K | 633.2K | 616.7K |
| Profit Margin | 4.5% | 3.6% | 3.5% |
| EBITDA | 1.32M | 1.18M | 1.27M |
| Free Cash Flow | 745.4K | 469.0K | 453.6K |
| Rev Growth | +3.4% | -9.1% | -0.5% |
| Debt/Equity | 0.78 | 0.66 | 0.81 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $266.28 | +0.73% | 74.3 | 468.50B |
| AMGN | Amgen Inc | $418.13 | +0.85% | 25.1 | 219.78B |
| GILD | Gilead Sciences Inc | $152.21 | +0.85% | — | 185.02B |
| VRTX | Vertex Pharmaceuticals Inc | $527.67 | +0.28% | 30.5 | 134.17B |
| REGN | Regeneron Pharmaceuticals | $752.25 | -4.54% | 18.8 | 81.31B |
| ALNY | Alnylam Pharmaceuticals Inc | $255.36 | -0.23% | 41.4 | 33.44B |